Epidemiologic approaches to the study of Parkinson's disease etiology

Epidemiology

Volumn 10, Issue 3, 1999, Pages 327-336

  Checkoway, Harvey ^a,b   Nelson, Lorene M ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Environmental exposures; Etiology; Genetic polymorphisms; Parkinson's disease; Smoking

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ARTICLE; CIGARETTE SMOKING; ENVIRONMENTAL EXPOSURE; GENETIC SUSCEPTIBILITY; HUMAN; LIFESTYLE; NEUROTOXICITY; PARKINSON DISEASE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL;

EID: 0032948286     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-199905000-00023     Document Type: Article

References (157)

1. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely, and Jones, 1817:1-66.
2. Agid Y. Parkinson's disease: pathophysiology. Lancet 1991;337:1321-1327.
3. Pahwa R, Koller WC. Defining Parkinson's disease and parkinsonism. In: Ellenberg JH, Koller WC, Langsten JW, eds. Etiology of Parkinson's Disease. New York: Marcel Dekker, 1995;1-54.
4. Duvoisin RC, Yahr MD. Encephalitis and parkinsonism. Arch Neurol 1965;12:227-239
5. Kessler II. Parkinson's disease in epidemiologic perspective. In: Schoenberg BS, ed. Advances in Neurology, vol. 19. New York: Raven Press, 1978; 355-383.
6. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219:979-980.
7. Tanner CM. Parkinson's disease. In: Gorelick PB, Alter M, eds. Handbook of Neuroepidemiology. New York: Marcel Dekker, 1994:253-280.
8. Ben-Shlomo Y. How far are we in understanding the cause of Parkinson's disease? J Neurol Neurosurg Psychiatry 1996;61:4-16.
9. Goldacre MJ. Cause-specific mortality: understanding uncertain tips of the disease iceberg. J Epidemiol Community Health 1993;43:491-496.
10. de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MMB, Maraganore DM. A population perspective on diagnostic criteria for Parkinson's disease. Neurology 1997:48:1277-1281.
11. Sutcliffe RLG, Meara JR. Parkinson's disease epidemiology in the Northampton District, England. Acta Neurol Scand 1992;1995;92:443-450.
12. de Rijk MC, Breteler MMB, Graveland GA, Ott A, Grobbee DE, van der Mèche FGA, Hofman A. Prevalence of Parkinson's disease in the elderly: The Rotterdam Study. Neurology 1995;45:2143-2146.
13. Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA. The epidemiology of Parkinson's disease in the County of Rogaland, Norway. Mov Disord 1995:10:541-549.
14. Trenkwalder C, Schwam J, Gebhard J, Ruland D, Trenkwalder P, Hense H-W, Oertel WH. Starnberg trial on epidemiology of parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 1995:52:1017-1022.
15. Mayeux R, Marder K, Cote LJ, Denaro J, Hemenegildo N, Mejia H, Tang M-X, Lantingua R, Wilder D, Gurland B, Hauser A. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in Northern Manhattan, 1938-1993. Am J Epidemiol 1995:142:820-827.
16. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl ] Med 1996;334:71-76.
17. Fall P-A, Axelson O, Fredriksson M, Hansson G, Lindvall B, Olsson J-E, Granerus A-K. Age standardized incidence and prevalence of Parkinson's disease in a Swedish community. J Clin Epidemiol 1996;49:637-641.
18. Chio A, Magnani G, Schiffer D. Prevalence of Parkinson's disease in Northwest Italy: comparison of trace methodology and clinical ascertainment of cases. Mov Disord 1998;13:400-405.
19. Ben-Shlomo Y, Sieradzan K. Idiopathic Parkinson's disease: epidemiology, diagnosis and management. Br J Gen Pract 1995:45:261-268.
20. Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologie observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 1996:46:1044-1050.
21. Kusumi M, Nakashima K, Harada H, Nakayama H, Takahashi K. Epidemiology of Parkinson's disease in Yonago City, Japan: comparison with a study carried out 12 years ago. Neuroepidemiology 1996:15:201-207.
22. Melcon MO, Anderson DW, Vergara RH, Rocca WA. Prevalence of Parkinson's disease in Junin Buenos Aires Province, Argentina. Mov Disord 1997:12:197-205.
23. Sasco A, Paffenbarger RS. Measles infection and Parkinson's disease. Am J Epidemiol 1985;122:1017-1031.
24. Matsumine H, Saito M, Shimoda-Matsubayashi S, Tanaka H, Ishikawa A, Nakagawa-Hattori Y, Yokochi M, Kobayashi T, Igarashi S, Takano H, Sanpei K, Koike R, Mori H, Kondo T, Miiutani Y, Schaffer AA, Yamamura Y, Nakamura S, Kuzuhara S, Tsuji S, Mizuno Y. Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25:2-27. Am J Hum Genet 1997:60:588-596.
25. Ludin SM, Ludin HP. Is Parkinson's disease of early onset a separate disease entity? J Neurol 1989;236:203-207.
26. Golbe LI. Young-onset Patkinson's disease: a clinical review. Neurology 1991:41:168-173.
27. Lanska DJ. The geographic distribution of Parkinson's disease mortality in the United States. J Neurol Sei 1997:150:63-70.
28. Kurtzke JF, Murphy FM. The changing patterns of death rates in parkinsonism. Neurology 1990;40:42-49.
29. Riggs JE, Schobert SS. Rising mortality due to Parkinson's disease and amyotrophic lateral sclerosis: a manifestation of the competitive nature of human mortality. J Clin Epidemiol 1992:45:1007-1012.
30. Ballard PA, Langston J W, Tetrud J W. Permanent human parkinsonism due to 1-methyI-4-pheny;-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985:35:949-956.
31. Tetrud JW, Langston JW, Garbe PL, Ruttenber AJ. Mild parkinsonism in persons exposed to 1-mehryl-1,4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurology 198939:1483-1487.
32. Snyder SH, D'Amato RJ. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology 1986:36:250-258.
33. Chiba K, Trevor A, Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984:120:574-578.
34. Cleeter MWJ, Cooper JM, Schapira AHV. Irreversible inhibition of mitochondrial Complex I by 1-metnyl-4-phenylpyridinium ion: evidence for free radical involvement. J Neurochem 1992:58:786-789.
35. Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991:40:63-68.
36. Gilham DE, Cairns W, Paine MJI, Modi S, Poulson D, Roberts GCK, Wolf CR. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in sit hybridization. Xenobiotica 1997:27:111-125.
37. Barbeau A, Roy M, Cloutier T, Plasse L, Paris S. Environmental and genetic factors in the etiology of Parkinson's disease. In: Yahr M, Bergmann K, eds. Advances in Neurology, vol. 45. New York: Raven Press, 1986; 299-306.
38. Scherman D, Desnon C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 1989;26:551-557.
39. Calne DB, McGeer E, Eisen A, Spencer P. Alzheimer's disease, Parkinson's disease, and motoneuron disease: abiotrophic interaction between aging and environment? Lancet 1986;ii:1067-1070.
40. Langston JW, Irwin I, Ricaurte GA. Neurotoxins, parkinsonism, and Paikinson's disease. Pharmacol Ther 1987:32:19-49.
41. Schapira AHV. Oxidative stress in Parkinson's disease. Neuropathol Appl Neurobiol 1995;21:3-9.
42. Knight ]A. Reactive oxygen species and the neurodegenerative disorders. Ann Clin Lab Sei 1997;27:11-25.
43. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357-366.
44. Mochizuki H, Mori H, Mizuno Y. Apoptosis in neurodegenerative disorders. J Neural Transm Suppl 1997:50:125-140.
45. Bums RS, Chiueh CC, Markey SP, Ebert MH, Jacobowia DM, Kopin LJ. A primate model of parkinsonism: selective destruction of dopaminergtc neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
46. Nagutsu T. Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res 1997:29:99-111.
47. Baez S, Segura-Aguilar J, Widersten M, Johnansson A-S, Mannervik B. Glutathione transferascs catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing cellular processes. Biochem J 1997;324:25-28.
48. Morens DM, Grandinetti A, Reed D, White LR. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995;45:1041-1051.
49. Haack DG, Baumann RJ, McKean HE, Jameson HG, Turbek JA. Nicotine exposure and Parkinson disease. Am] Epidemiol 1981;114:191-200.
50. Stem M, Dulaney E, Gruber SB, Golbe L, Bergen M, Hurtig H, Gollump S, Stolley P. The epidemiology of Parkinson's disease: a case-control study of young-onset and old-onset patients. Arch Neurol 1991;48:903-907.
51. Jiménez-Jiménez FJ, Mateo D, Giménez-Roldan S. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: a case-control study. Mov Disord 1992;7:339-344.
52. Butterfield PG, Valanis EG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson's disease. Neurology 1993;43:1150-1158.
53. Mayeux R, Ting M-X, Marder K, Cote LJ, Stem Y. Smoking and Parkinson's disease. Mov Disord 1994:9:207-212.
54. Martyn CN, Osmond C. Parkinson's disease and the environment in early life. J Neurol Sei 1995;132:201-206.
55. De Michelle G, Filla A, Volpe G, De Marco V, Gogliettino A, Ambrosio G, Marconi R, Castellano AE, Campanella G. Environmental and genetic risk factors in Parkinson's disease: a case-control study in southern Italy. Mov Disord 1996:11:17-23.
56. Hellenbrand W, Seidler A, Robra B-P, Vieregge P, Oertel WH, Joerg J, Nischan P, Schneider E, Ulm G. Smoking and Parkinson's disease: a case-control study in Germany. Int J Epidemiol 1997:26:328-339.
57. Kahn HA. The Dom study of smoking and mortality among U.S. veterans: report on eight and one-half years of observation. Natl Cancer Inst Monog 19. Bethesda, MD: U.S. Dept Health, Education and Welfare. 1966:1-27.
58. Sasco AJ, Paffenbarger RS. Smoking and Parkinson's disease. Epidemiology 1990:1:460-465.
59. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 1994:139:1129-1138.
60. Morens DM, Grandinetti A, Davis JW, Ross GW, White LR, Reed D. Evidence against the operation of selective mortality in explaining the association between cigarette smoking and reduced occurrence of idiopathic Parkinson's disease. Am J Epidemiol 1996:144:400-404.
61. Paulson GW, Dadmehr N. Is there a premorbid personality typical for Parkinson's disease? Neurology 1991;41(suppl 2):73-76.
62. Riederer P, Konradi C, Hebestreit G, Youdim MBH. Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol Scand 1989:126:41-45.
63. Fowler JS, Volkow ND, Wang G-J, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schyler D, Wold AP, Wamer D, Zezulkova I, Cilento R. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996-379:733-736.
64. Wei Q, Yeung M, Jurma OP, Andersen JK. Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increase free radical damage and sensitivity to MPTP. J Neurosci Res 1996:46:666-673.
65. Damier P, Kastner A, Agid Y, Hirsch EC. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? Neurology 1996:46:1262-1269.
66. Tanner CM, Cohen JC, Summerville BC, et ai Vitamin use and Parkinson's disease. Ann Neurol 1988;23:182.
67. Golbe L, Farrell T, Davis P. Follow-up study of early-life protective and risk factors in Parkinson's disease. Mov Disord 1990;5:66-70.
68. Hellenbrand W, Boeing H, Robra B-P, Seidler A, Viergge P, Nischan P, Joerg J, Oertel WH, Schneider E, Ulm G. Diet and Parkinson's disease II: a possible role for the past intake of specific nutrients. Results from a self'administered food-frequency questionnaire in a case-control study. Neurology 1996;47:644-650.
69. Viergge P, Maravic C, Fredrich HJ. Life-style and dietary factors early and late in Parkinson's disease. Can ] Neurol Sei 199Z;19:170-173.
70. Morens DM, Grandinetti A, Waslein CI, Park CB, Ross GW, White LR. Case-control study of idiopathic Parkinson's disease and dietary vitamin E intake. Neurology 1996;46:1270-1274.
71. Scheider WL, Hershey LA, Holmlund T, Marshall JR, Freudenheim JL. Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Mov Disord 1997:12:190-196.
72. Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, Lojacono N, Cote L, Mayeux R. Dietary iron, animal fats, and risk of Parkinson's disease. Mov Disord 199S;13(suppl 1):13-16.
73. Anderson C, Checkoway H, Franklin GM, Beresford S, Smith-Weller T, Swanson PD. Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov Disord 1999;14:21-27.
74. Cotzias GC. Manganese in health and disease. Physiol Rev 1958:38:503-532.
75. Vigliani EC. Carbon disulfide poisoning in viscose rayon factories. Br J Ind Med 1954;11:235-241.
76. Tanner CM. Occupational and environmental causes of parkinsonism. Occup Med 1992;7:503-513.
77. Hubble JP, Cao T, Hassanein RES, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology 1993:43:1693-1697.
78. Hertzman C, Wiens M, Snow B, Kelly S, Calne D. A case-control study of Parkinson's disease in a horticultural region of British Columbia. Mov Disord 1994:9:69-75.
79. Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992:42:1328-1335.
80. Seider A, Hellenbrand W, Robra B-P, Viergge P, Nischan P, Joerg J, Oertel WH, Ulm G, Schneider E Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996:46:1275-1284.
81. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC. Environmental risk factors for Parkinson's disease: a case-control study in Taiwan. Neurology 1997:48:1583-1588.
82. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson's disease with exposure to pesticides, fanning, well water, and rural living. Neurology 1998;50:1346-1350.
83. Hertzman C, Wiens M, Bowering D, Snow B, Calne D. Parkinson's disease: a case-control study of occupational and environmental risk factors. Am J Ind Med 1990:17:349-355.
84. Koller W, Veter-Overfield B, Gray C, Alexander C, Chin T, Dolezal J, Hassanein R, Tanner C. Environmental risk factors in Parkinson's disease. Neurology 1990:40:1218-1221.
85. Wong GF, Gray CS, Hassanein RS, Koller WC. Environmental risk factors in siblings with Parkinson's disease. Arch Neurol 1991:48:287-289.
86. Barbeau A, Roy M, Bernier G, Campanella G, Paris S. Ecogenetics of Parkinson's disease: prevalence and environmental aspects in rural areas. Can J Neurol Sei 1987:14:36-41.
87. Rajput AH, Uitti Rj, Stem W, Laverty W, O'Donnell K, O'Donnell D, Yuen WK, Dua A. Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. Can J Neurol Sci 1987:14:414-418.
88. Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to rural environmental factors: a population-based case-control study. Can J Neurol Sei 1991:18:279-286.
89. Rocca WA, Anderson DW, Meneghini F, Grigoletto F, Morgante L, Reggio A, Savattieri G, Di Perri R. Occupation, education, and Parkinson's disease: a case-control study in an Italian population. Mov Disord 1996; 11:201-206.
90. Marder K, Logroscino G, Alfaro B, Mejia H, Halim A, Louis E, Cote L, Mayeux R. Environmental risk factors for Parkinson's disease in an urban multiethnic community. Neurology 1998;50:279-281.
91. 'Duvoisin RC. The genetics of Parkinson's disease. Adv Neurol 1993;60: 306-314.
92. Golbe LI. The genetics of Parkinson's disease: a reconsideration. Neurology 1990:40(suppl 3):7-14.
93. Maraganore DM, Harding AE, Marsden CD. A clinical and genetic study of familial Parkinson's disease. Mov Disord 1991;6:20-211.
94. Lazzarini AM, Myers RH, Zimmerman TR, Mark MH, Golbe LI, Sage JI, Johnson WG, Duvoisin RC. A clinical genetic study of Parkinson's disease: evidence for dominant transmission. Neurology 199;44:499-506.
95. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroos ES, Pho LT, Schaffer AA, Lazzarini AM, Nussbaum RL, Duvoisin RC. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996;274:1197-1199.
96. Polmeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Durra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazsrini AM, Duvoisin RC, Di lorio G, Golbe LI, Nussbaum RL. Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 1997:276:2045-2047.
97. Gasser T, Muller-Myshok B, Wszolek ZK, Durr A, Vaughan JR, Bonifati V, Meco G, Bereznai B, Oehlmann R, Agid Y, Brice A, Wood N. Genetic complexity and Parkinson's disease. Science 1997;277:388-389.
98. Farrer M, Wavrant-De Vrie:e F, Crook R, Boles L, Perez-Tur J, Hardy J, Johnson WG, Steele J, Maraganore D, Gwinn K, Lynch T. Low frequency of a-synuclein mutations in familial Parkinson's disease. Ann Neurol 199S;43:394-397.
99. 209A) in 100 patients with younger onset Parkinson's disease. Neurology 1998;50:513-514.
100. Nelson LM, Chan P, Tanner CM, Van Den Eeden SK: Absence of the a-synuclein gene missense mutation (G209A) in 40 patients with a family history of Parkinson's disease. Neurology 1998;50(suppl):A197.
101. Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, Bereznai B, Fabrizio E, Vieregge P, Horstmann RD: A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998; 18:262-265.
102. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983:33:815-824.
103. Eldridge R, Ince SE. The low concordance rate for Parkinson's disease in twins. Neurology 1984:34:1354-1356.
104. Marsden CD. Parkinson's disease in twins. J Neurol Neurosurg Psychiatry 1987:50:105-106.
105. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langsten JW. Parkinson disease in twins: an etiologic study. JAMA 1999: 281341-346.
106. Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson's disease in patients and siblings of patients. Ann Neurol 1994:36:659-661.
107. Wood N. Genes and parkinsonism. J Neurol Neurosurg Psychiatry 1997; 62305-309.
108. Checkoway H, Farin FM, Costa-Mallen P, Kirchner SC, Costa LG. Genetic polymorphisms in Parkinson's disease. Neurotoxicology 1998:19:635-643.
109. Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993; 33368-372.
110. Ho SL, Kapadi AL, Ramsden DB, Williams AC. An allelic association study of monoamine oxidase B in Parkinson's disease. Ann Neurol 1995; 37:403-405.
111. Nanko S, Ueki A, Hattori M. No association between Parkinson's disease and monoamine oxidase A and B gene polymorphisms. Neurosci Lett 1996;204:125-127.
112. Costa P, Checkoway H, Levy D, Smith-Weller T, Franklin GM, Swanson PD, Costa LG. Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson's disease. Am J Med Genet 1997:74: 154-156.
113. Plante-Bordeneuve V, Tausstg D, Thomas F, Said G, Wood NW, Marsden CD, Harding AE. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele. Neurology 1997:48:1589-1593.
114. Comings DE, Comings BG, Muhleman D, Dietz G, Shahbahrami B, Tast D, Knell E, Kocsis P, Baumgarten R, Kovacs BW, Levy DL, Smith M, Borison RL, Evans DD, Klein DN, MacMurray J, Tosk JM, Sverd J, Gysin R, Flanagan SD. The dopamine D2 receptor locus as a modifying gene in neuropsychiatrie disorders. JAMA 1991:266:1793-1800.
115. Nanko S, Ueki A, Hattori M, Dai XY, Tuskasa S, Fukuda R, Ikeda K, Kazamatsuri H. No allelic association between Parkinson's disease and dopamine D2, D3, and D4 receptor gene polymorphisms. Am J Med Genet 1994:54361-364.
116. Le Couleur DG, Leighton PW, McCann SJ, Pond SM. Association of a polymorphism in the dopamine-transponer gene with Parkinson's disease. Mov Disord 1997:12:760-763.
117. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985; ii:1213-1216.
118. Steventon GB, Heafield MTE, Sturman SG, Waring RH, Williams AC, Ellingham J. Degenerative neurological disease and debrisoquine-4-hydroxylation capacity. Med Sei Res 1989;17:163-164.
119. Benítez J, Ladern JM, Jiménez-Jiménez FJ, Martînez C, Puerto AM, Valdivielso MJ, Llerena A, Cobaleda J, Munoz JJ. Oxidative polymorphism of debrisoquine in Parkinson's disease. J Neutol Neurosurg Psychiatry 1990:53:289-292.
120. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Neben DW, Gelboin HV, Hardwick JP, Meyer UA. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988:331:442-446.
121. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990336:529-532.
122. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991;133-41.
123. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339: 1017-1018.
124. Smith CA, Gough AC, Leigh PN, Summers BA, Harding AE, Maraganore DM, Sturman SG, Schapira AH, Williams AC, Maranganore DM. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992:339:1375-1377.
125. Kurth MC, Kurth JH. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am ] Med Genet 1993;48:166-168.
126. Tsuneoka Y, Matsuo Y, Iwahashi K, Takeuchi H, Ichikawa Y. A novel cytochrome P-450IID6 gene associated with Parkinson's disease. J Biochem 1993:114:263-266.
127. Lucotte G, Turpin J-C, Gerard N, Panserai S, Krishnamoorthy R. Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson's disease patients and their families. Am J Med Genet 1996:67:361-365.
128. McCann SJ, Pond SM, James KM, Le Gouteur DG. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta analysis. J Neurol Sei 1997: 153:50-53.
129. Kosel S, Lucking CB, Egensperger R, Mehraein P, Graeber MB. Mitochondria! NADH dehydrogenase and CYP2D6 genotypes in Lewy-body parkinsonism. J Neurosci Res 1995;44:174-183.
130. Wang SL, Lai MD, Lai ML, Huang JD. R296C and other CYP2D6 mutations in Chinese. Pharmacogenetics 1995;5:385-388.
131. Bordet R, Broly F, Destee A, Libersa C, Lafitte JJ. Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease. Clin Neuropharmacol 1996:19:213-221.
132. Diederich N, Hilger C, Goetz CG, Keipes M, Hentges F, Vieregge P, Metz H. Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol 1996:40:463-465.
133. Bandmann O, Vaughan J, Holmans, Marsden CD, Wood NW. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 1997:350:1136-1139.
134. Plante-Bordeneuve V, Davis MB, Maraganore DM, Marsden CD, Harding AE. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1994:57:911-913.
135. Agundez JA, Jiménez-Jiménez FJ, Luengo A, Bemal ML, Molina JA, Ayuso L, Vazquez A, Parra J, Duarte J, Coria F. Association between the oxidative polymorphism and the early onset of Parkinson's disease. Clin Pharmacol Ther 1995:57:291-298.
136. Sandy MS, Armstrong M, Tanner CM, Daly AK, Di-Monte DA, Langston JW, Idle JR. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology 1996:47:225-230.
137. Langston JW. Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies. Neurology 1990;40(suppl 3):61-66.
138. Williams A, Steventon G, Sturman S, Waring R. Xenobiotic enzyme profiles and Parkinson's disease. Neurology 1991;41(suppl 2):29-32.
139. Checkoway H, Costa LG, Woods JS, Castoldi AF, Lund BO, Swanson PD. Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease. J Neural Transm Park Dis Sect 1992;4: 283-290.
140. Morimoto Y, Murayama N, Kuwano A, Kondo I, Yamashita Y, Mizuno Y. Association of a polymorphism of the monoamine oxidase B gene with Parkinson's disease in a Japanese population. Am J Med Genet 1995;60: 570-572.
141. Checkoway H, Franklin GM, Costa-Mallen P, Smith-Weller T, Dilley J, Swanson PD, Costa LG. A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease. Neurology 1998; 50:1458-1461.
142. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, Rahmani Z, Kriius A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Herzfeldt B, Van den Bergh R, Hung WY, Bird T, Deng G, Mulder DW, Smyth C, Laing NO, Soriano E, Pericak-Vance MA, Haines J, Rouleau GA, Gusella JS, Horviti HR, Brown RH Jr. Mutations in Cu/Zn Superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 1993:362:59-62.
143. Strittmatter WJ, Saunders AM, Schmechal D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-affinity binding to /3-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. Proc Natl Acad Sei USA 1993:90:1977-1981.
144. Bandmann O, Davis MB, Marsden CD, Harding AE. Sequence of the Superoxide dismutase 1 (SOD 1) gene in familial Parkinsons' disease. J Neurol Neurosurg Psychiatry 1995:59:90-91.
145. Koller WC, Glatt SL, Hubble JP, Paolo A, Troster AI, Handler MS, Horvat RT, Martin C, Schmidt K, Karst A, Wijsman EM, Yu C-E, Schellenbcrg GD. Apoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol 1995:37:242-245.
146. Whitehead AS, Bertrandy S, Finnan F, Butler A, Smith GD, Ben-Shlomo Y. Frequency of apolipoprotein E epsilon 4 allele in a case-control study of early onset Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61: 347-351.
147. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees A]: What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
148. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neural 1992;32:S125-S127.
149. Marsden CD. Parkinson's disease. Lancet 1990335:948-952.
150. Langsten JW. Predicting Parkinson's disease. Neurology 1990;40(suppl 3):70-74.
151. Wacholder S, Silverman DT, McLaughlin ]K, Mandel JS. Selection of controls in case-control studies. II. Types of controls. Am J Epidemiol 1992:1029-1041.
152. Willett WC. Nutritional Epidemiology, 2nd ed. New York: Oxford University Press, 1998.
153. McGuire V, Nelson LM, Koepsell TD, Checkoway H, Longstreth WT Jr. Assessment of occupational exposures in community-based studies. Annu Rev Public Health 1998:19:35-53.
154. Steinberg KK, Sanderlin KC, Ou Chin-Y, Hannon WH, McQuillan CM, Sampson EJ. DNA banking in epidemiologic studies. Epidemiol Rev 1997; 19:156-162.
155. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994:265:2037-2048.
156. Hwang S-J, Beaty TH, Liang K-Y, Coresh J, Khoury MJ. Minimum sample size estimation to detect gene-environment interaction in case-control designs. Am J Epidemiol 1994:140:1029-1037.
157. Alavanja MCR, Sandier DP, McMaster SB, Zahm SH, McDonnell CJ, Lynch CF, Pennybacker M, Rothman N, Dosemeci M, Bond AE, Blair A. The agricultural health study. Environ Health Perspect 1996;104: 362-369.